Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C
Trial details
- Registry ID
- NCT05905926
- Phase
- Phase 3
The FDA approved Tenapanor (IBSRELA) on 12 Sep 2019.
Drug identity checked against registry records
Also recorded as IBSRELA; Ibsrela; RDX5791, AZD1722
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-CNCT05905926 | Ardelyx | Phase 3 | Enrolling by invitation | 2031-07Estimated |
| 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 YrsNCT06553547 | Ardelyx | Phase 2 | Completed | 2026-07-07Actual |
| A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on DialysisNCT03427125 | Ardelyx | Phase 3 | Completed | 2019-11-15Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2019-09-12Day | Tenapanor | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA211801", "applicant_as_listed_by_fda": "ARDELYX INC", "brand_names": ["IBSRELA"], "active_ingredients": ["TENAPANOR HYDROCHLORIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20190912", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |